The overall ratings of four Pharmaceutical stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Pernix Therapeutics Holdings’ (NASDAQ:PTX) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Momentum, and Earnings Revisions, PTX also gets an F. The trailing PE Ratio for the stock is 53.90. For a full analysis of PTX stock, visit Portfolio Grader.
Depomed’s (NASDAQ:DEPO) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Depomed is a specialty pharmaceutical company focused on the development and commercialization of differentiated products that address large and growing markets and are based on proprietary oral drug delivery technologies. The stock gets F’s in Equity, Cash Flow, and Margin Growth. For more information, get Portfolio Grader’s complete analysis of DEPO stock.
Shire PLC ADR (NASDAQ:SHPG) earns a D this week, moving down from last week’s grade of C. For a full analysis of SHPG stock, visit Portfolio Grader.
Omeros Corp. (NASDAQ:OMER) experiences a ratings drop this week, going from last week’s C to a D. Omeros is a biopharmaceutical company developing a pipeline of product candidates for use in orthopedics, rheumatology, urology, cardiovascular medicine, general surgery and pain management. The stock gets F’s in Earnings Revisions and Cash Flow. For more information, get Portfolio Grader’s complete analysis of OMER stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.